The utility of the Cambridge Behavioural Inventory in neurodegenerative disease
- 1Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
- 2Department of Clinical Neuroscience, Addenbrooke’s Hospital, Cambridge, UK
- 3MRC-Cognition and Brain Sciences Unit, 15 Chaucer Road, Cambridge, UK
- Professor John Hodges, Prince of Wales Medical Research Institute, University of New South Wales, Barker St, Randwick, Sydney 2031, Australia;
- Received 4 April 2007
- Revised 21 June 2007
- Accepted 20 July 2007
- Published Online First 10 September 2007
We investigated the utility of the Cambridge Behavioural Inventory (CBI), a carer-completed questionnaire, in a large cohort with Parkinson’s disease (PD) (n = 215). In a sub-cohort of 112 patients with PD, the CBI was found to be a valid instrument compared with the Neuropsychiatric Inventory, PDQ-39 and UPDRS, with high internal consistency. Furthermore, in the whole cohort, the CBI was sensitive to changes in behaviour with disease progression. Comparison between CBI scores in PD and other neurodegenerative diseases, including Huntington’s disease (HD) (n = 75), Alzheimer’s disease (AD) (n = 96) and frontal variant frontotemporal dementia (fvFTD) (n = 64), revealed distinct profiles for each disease. Predominant deficits were “sleep”’ and “self care” in PD; “memory” in HD and AD; and “motivation” and “stereotypic behaviours” in fvFTD. The CBI is a robust, easy-to-use and valid instrument, which has the capacity to discriminate between neurodegenerative diseases, and may be of value in monitoring therapeutic interventions.
Competing interests: None declared.